Sanofi’s real-world study shows that infant immunization with BEYFORTUS® offers stronger protection against RSV-related hospitalizations compared to maternal immunization strategies.
Explore the frontiers of Biotechnology, Pharma/Biopharma industry and Science with BiotechReality. We publish news, reports, views and articles.
Sanofi’s real-world study shows that infant immunization with BEYFORTUS® offers stronger protection against RSV-related hospitalizations compared to maternal immunization strategies.
A SciRealityPress Associate
Contents in the website is licensed under CC BY-NC 4.0
Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio